Martin Babler has served as President, Chief Executive Officer and Chairman of the Board of Alumis Inc. since September 2021. He previously served as President and Chief Executive Officer of Principia Biopharma Inc. from 2011 until its acquisition by Sanofi S.A. in 2020, and as President and Chief Executive Officer of Talima Therapeutics, Inc. Earlier in his career, he held several leadership positions at Genentech, Inc., most notably as Vice President, Immunology Sales and Marketing. Mr. Babler currently serves on the board of directors of Prelude Therapeutics, Inc.